PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34857198-6	2021	Vitamin D also have its effect on angiotensin converting enzyme (ACEII) inhibitor through which the COVID-19 virus makes cell entry.	Vitamin D	0-9	angiotensin I converting enzyme	Homo sapiens	34-63	
32613681-9	2021	Experimentally, vitamin D increases the ratio of angiotensin-converting enzyme 2 (ACE2) to ACE, thus increasing angiotensin II hydrolysis and reducing subsequent inflammatory cytokine response to pathogens and lung injury.	Vitamin D	16-25	angiotensin I converting enzyme	Homo sapiens	82-85	
29079468-0	2017	Addition of vitamin D reverses the decline in GFR following treatment with ACE inhibitors/angiotensin receptor blockers in patients with chronic kidney disease.	Vitamin D	12-21	angiotensin I converting enzyme	Homo sapiens	75-78	
26873590-10	2016	In non-users of supplemental vitamin D, after adjustment for age and gender, negative associations were found for severe polypharmacy, metformin, sulphonamides and urea derivatives (SUDs), vitamin K antagonists, cardiac glycosides, loop diuretics, potassium-sparing diuretics, ACE inhibitors, and serotonin reuptake inhibitors; for non-selective monoamine reuptake inhibitors (NSMRIs) the association was positive.	Vitamin D	29-38	angiotensin I converting enzyme	Homo sapiens	277-280	
24385337-5	2014	PubMed was searched for human epidemiological and clinical studies published until early 2013, investigating the relationship between vitamin D blood levels and use of drugs from one of the following groups: proton pump inhibitors (PPIs), biguanides, vitamin K antagonists, platelet aggregation inhibitors, thiazide diuretics, loop diuretics, beta-blocking agents, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II antagonists, statins, benzodiazepines, and antidepressants.	Vitamin D	134-143	angiotensin I converting enzyme	Homo sapiens	391-420	
24385337-5	2014	PubMed was searched for human epidemiological and clinical studies published until early 2013, investigating the relationship between vitamin D blood levels and use of drugs from one of the following groups: proton pump inhibitors (PPIs), biguanides, vitamin K antagonists, platelet aggregation inhibitors, thiazide diuretics, loop diuretics, beta-blocking agents, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II antagonists, statins, benzodiazepines, and antidepressants.	Vitamin D	134-143	angiotensin I converting enzyme	Homo sapiens	422-425	
17142213-0	2006	Effects of ACE gene polymorphism on vitamin D therapy according to parathyroid hormone level in patients on hemodialysis.	Vitamin D	36-45	angiotensin I converting enzyme	Homo sapiens	11-14	
17142213-3	2006	The aim of this study was to evaluate the association of genetic influences of angiotensinconverting enzyme (ACE) gene polymorphisms with response to vitamin D therapy among patients on hemodialysis (HD).	Vitamin D	150-159	angiotensin I converting enzyme	Homo sapiens	79-107	
17142213-3	2006	The aim of this study was to evaluate the association of genetic influences of angiotensinconverting enzyme (ACE) gene polymorphisms with response to vitamin D therapy among patients on hemodialysis (HD).	Vitamin D	150-159	angiotensin I converting enzyme	Homo sapiens	109-112	
17142213-7	2006	Patients with the DD allele (group DD) of ACE gene polymorphism had (1) significantly elevated mean 5-y intact parathyroid hormone levels when compared with the non-DD group (P=.009), and (2) significantly elevated oral and intravenous 5-y cumulative doses of vitamin D.	Vitamin D	260-269	angiotensin I converting enzyme	Homo sapiens	42-45